Compare · DFTX vs PRDS
DFTX vs PRDS
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Pardes Biosciences Inc. (PRDS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and PRDS operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.60B, about 7.0x PRDS ($657.5M).
- DFTX has hit the wire 8 times in the past 4 weeks while PRDS has been quiet.
- DFTX has more recent analyst coverage (8 ratings vs 3 for PRDS).
- Company
- Definium Therapeutics Inc.
- Pardes Biosciences Inc.
- Price
- $32.12-6.23%
- $2.19+1.39%
- Market cap
- $4.60B
- $657.5M
- 1M return
- -17.01%
- -
- 1Y return
- +144.26%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 8
- 0
- Recent ratings
- 8
- 3
PRDS
Pardes Biosciences Inc.
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Analyst initiated coverage on Definium Therapeutics with a new price target
- Chief Medical Officer Karlin Daniel sold $396,894 worth of shares (10,853 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 792,846 units (SEC Form 4) (withholding obligation)
- Chief Executive Officer Barrow Robert sold $1,153,784 worth of shares (31,550 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 2,213,090 units (SEC Form 4) (for withholding tax)
- Chief Commercial Officer Wiley Matthew T. sold $113,257 worth of shares (3,097 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.86% to 359,036 units (SEC Form 4) (for tax liability)
- Chief Legal Officer Sullivan Mark sold $513,845 worth of shares (14,051 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 494,228 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Roberts Brandi sold $123,497 worth of shares (3,377 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.85% to 394,528 units (SEC Form 4) (withholding tax)
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form 144 filed by Definium Therapeutics Inc.
- SEC Form 144 filed by Definium Therapeutics Inc.
Latest PRDS
- SEC Form 15-12G filed by Pardes Biosciences Inc.
- SEC Form EFFECT filed by Pardes Biosciences Inc.
- SEC Form EFFECT filed by Pardes Biosciences Inc.
- SEC Form 4: Tananbaum James B. returned 16,813,146 shares to the company and acquired 1,000 shares
- SEC Form SC 13D/A filed by Pardes Biosciences Inc. (Amendment)
- SEC Form 4: Wiggans Thomas G closing all direct ownership in the company
- SEC Form 4: Varney Michael David closing all direct ownership in the company
- SEC Form 4 filed by Smaldone Alsup Laurie
- SEC Form 4 filed by Pottage John C Jr
- SEC Form 4: Lopatin Uri A closing all direct ownership in the company